Had a great last day at #TLM2025 with inspiration and food for 🤔

👀 all 7 women @aasldnews.bsky.social presidents in one room (‼️) for the Women’s Luncheon

🔥🔥🔥discussion by @LaurenFeldMD and division chiefs on recruitment & retention of women hepatologists

#liversky

➡️What happens when you increase salary transparency?

➡️What is on a chief’s 🧠when negotiating a new hire?

➡️How to ⚖️ accommodations & consistency?

Find out in our 🔥🔥 #TLM2025 panel

@aasldnews.bsky.social #liversky @ast-whcop.bsky.social @ast-licop.bsky.social

📣 NEW 💫 class of @aasldnews.bsky.social Women’s Leadership Development program mentees & mentors

It was lovely to celebrate you with an inspiring keynote talk from #AASLD25 President Dr. Grace Su

Looking forward to the year ahead!

#TLM2025 #liversky #gisky

➡️What #livertransplant candidates should get #GLP1-RA?

➡️Best timing for #bariatricsurgery in transplant?

➡️Data for #GLP1-RA in #cirrhosis?

🚨check out our @amjtransplant.bsky.social best practices for #obesity & liver transplant 👇
doi.org/10.1016/j.aj...

#liversky #GIsky #transplant

🚨 1st output from @AST_LICOP #obesity & #livertransplant conf!

➡️ anti-obesity meds & surg. underutilized

➡️ #incretins promising pre- & post-txp

➡️ #AOM & #bariatric surg. complementary, not either/or

#liversky #GIsky

journals.lww.com/lt/abstract/99…

@atoosarabiee.bsky.social reviewing peri-op mgmt of #cirrhosis at #AHNGI&LiverSummit2025

🔹Use VOCAL-Penn for pre-op risk stratification

🔹Pre-surgical #TIPS in CSPH not ready for prime time

🔹🚫 prophylactic transfusion prior to surgery

#liversky #GIsky

🤔 Which patients with #PVT should get AC?

🤔Do you band first?

🤔What is data behind DOAC for PVT?

🚨🚨AGA Clinical Practice Update on PVT Mgmt

www.gastrojournal.org/article/S001...

pragmatic review for busy GI with helpful algorithm 👀⬇️

#liversky #gisky #medsky

Packed house at Women’s luncheon for inspiring talk by past #AASLD president Dr. Teresa Wright, great way to close out my time at #TLM2024 💪💪🤸‍♀️

#TLM2024 #TARGETNASH
impact of GLP-1 on clinical outcomes in #cirrhosis

non-GLP-users:
⬆️ decomp HR 1.69
⬆️ mortality HR 2.28

💪 large, real world, clinical

➡️ lingering questions:

- role of muscle mass changes & outcomes in GLP users?

- is lack of GLP a marker for lack of access?

#liversky

Great pHTN session at #TLM2024 ➡️ statin, AC, & anti-fibrotics are promising
➡️ carvedilol for all
➡️ preemptive #TIPS is life-saving with NNT 4️⃣‼️

#TLM2024 #liversky #portalhypertension
@atoosarabiee.bsky.social